ZRT2 Antibody

What is ZO-2 and why is it important in research?

ZO-2 (also known as TJP2 or tight junction protein 2) is a 1190-amino acid protein belonging to the MAGUK (membrane-associated guanylate kinase) family. It functions primarily at tight junctions between epithelial and endothelial cells but also localizes to the nucleus. ZO-2 is critical for studying cell barrier function, cell-cell communication, and various disease processes including cancer metastasis and inflammatory conditions. The protein's dual localization (membrane and nuclear) makes it particularly interesting for researchers investigating cellular signaling mechanisms .

What types of ZO-2 antibodies are available for research?

ZO-2 antibodies are available in several formats for different research applications:

• Host species: Rabbit, mouse, and guinea pig antibodies are most common

• Clonality: Both monoclonal and polyclonal antibodies are available

• Conjugation status: Unconjugated or conjugated with various tags (biotin, Cy3, DyLight488)

• Reactivity profile: Antibodies with reactivity to human, mouse, rat, and other species

• Purification methods: Affinity-purified antibodies offer higher specificity for critical applications

What are the main applications for ZO-2 antibodies?

ZO-2 antibodies are validated for multiple techniques including:

• Western Blotting (WB)

• Immunohistochemistry (IHC)

• Immunocytochemistry (ICC)

• Immunofluorescence (IF)

• Immunoprecipitation (IP)

• ELISA

• Flow Cytometry (FCM)

The choice of application should guide your antibody selection, as not all antibodies perform equally across different techniques.

How do I validate a ZO-2 antibody before use in critical experiments?

Proper antibody validation is essential for reproducible research. A comprehensive validation should include:

• Target confirmation: Verify binding to recombinant ZO-2 protein

• Specificity testing: Use ZO-2 knockout or knockdown samples as negative controls

• Cross-reactivity assessment: Test for binding to other ZO family members (ZO-1, ZO-3)

• Application-specific validation: Optimize for your specific application and experimental conditions

• Reproducibility testing: Confirm consistent performance across multiple experiments

Never rely solely on manufacturer claims; perform validation in your specific experimental system and conditions .

What are the optimal fixation and permeabilization methods for ZO-2 immunofluorescence?

For optimal ZO-2 immunofluorescence staining:

• Fixation:

  • For membrane-associated ZO-2: 4% paraformaldehyde (PFA) for 10-15 minutes at room temperature

  • For nuclear ZO-2: Methanol fixation (-20°C for 10 minutes) often provides better nuclear epitope accessibility

• Permeabilization:

  • 0.1-0.2% Triton X-100 for 5-10 minutes for general permeabilization

  • 0.5% saponin may better preserve membrane structures while allowing antibody access

• Blocking:

  • 5% normal serum (from same species as secondary antibody) with 1% BSA for 30-60 minutes

Always optimize these conditions for your specific cell type and antibody, as tight junction proteins can be sensitive to fixation artifacts .

How can I troubleshoot weak or absent ZO-2 staining in immunofluorescence?

If experiencing weak or absent ZO-2 staining:

• Epitope masking: Try different fixation methods as mentioned above

• Antibody concentration: Titrate antibody concentration (typically 1-10 μg/ml range)

• Incubation conditions: Extend primary antibody incubation (overnight at 4°C)

• Antigen retrieval: For tissue sections, heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Signal amplification: Consider using biotin-streptavidin amplification systems

• Antibody quality: Verify antibody activity with positive control samples

• Expression levels: Confirm ZO-2 expression in your experimental system by Western blot

How do I distinguish between membrane and nuclear ZO-2 in co-localization studies?

ZO-2 exhibits dual localization at tight junctions and in the nucleus, which requires careful experimental design:

• Subcellular fractionation: Physically separate membrane and nuclear fractions before Western blotting

• Confocal microscopy: Use Z-stack imaging to differentiate membrane versus nuclear localization

• Co-staining markers:

  • Membrane ZO-2: Co-stain with other tight junction proteins (occludin, claudins)

  • Nuclear ZO-2: Co-stain with nuclear markers (DAPI, lamin)

• Stimulation conditions: Nuclear translocation can be induced by specific stimuli (growth factors, stress conditions)

• Quantification: Use image analysis software to quantify relative distribution between compartments

What controls are essential when studying ZO-2 phosphorylation states?

When investigating ZO-2 phosphorylation:

• Phosphatase controls: Include samples treated with lambda phosphatase to confirm phospho-specificity

• Phosphorylation inducers: Use positive controls with treatments known to induce ZO-2 phosphorylation

• Phospho-specific antibodies: Verify that antibodies recognize specific phosphorylation sites

• Phospho-mimetic mutants: Consider using mutant constructs (S→D or S→E) as positive controls

• Mass spectrometry validation: Confirm phosphorylation sites when feasible

• Kinase inhibitors: Include appropriate kinase inhibitors as negative controls

These controls help distinguish authentic phosphorylation signals from artifacts .

How can I effectively use ZO-2 antibodies in co-immunoprecipitation studies?

For successful ZO-2 co-immunoprecipitation experiments:

• Lysis buffer optimization:

  • Standard IP buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate

  • For membrane proteins: Add 0.1% SDS or consider milder detergents like digitonin

  • Include protease and phosphatase inhibitors

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation

  • Select antibodies recognizing epitopes unlikely to be masked by protein interactions

• Cross-linking considerations:

  • Formaldehyde (1%) cross-linking can stabilize transient interactions

  • DSP or DTSSP can be used for reversible cross-linking

• Controls:

  • IgG control from same species as ZO-2 antibody

  • Input sample (pre-IP lysate)

  • Reverse IP when studying specific interactions

What criteria should I use when selecting between different ZO-2 antibodies?

Request validation data specific to your application before purchase. When possible, test multiple antibodies in parallel to identify the best performer for your specific experimental system .

How do I interpret conflicting results from different ZO-2 antibodies?

Conflicting results between antibodies are common and may reflect:

• Different epitopes: Antibodies targeting different domains may detect distinct ZO-2 isoforms or conformations

• Post-translational modifications: Some epitopes may be masked by phosphorylation or other modifications

• Specificity issues: Cross-reactivity with ZO-1 or ZO-3 may occur with some antibodies

• Technical variables: Different optimal conditions for each antibody

• Sample preparation differences: Extraction methods may differentially preserve epitopes

To resolve conflicts:

• Use genetic models (knockouts, knockdowns) as definitive controls

• Employ multiple antibodies targeting different epitopes

• Confirm with non-antibody techniques (mass spectrometry, RNA analysis)

• Consider isoform-specific detection methods

What are the most common causes of irreproducibility when working with ZO-2 antibodies?

Poor reproducibility with ZO-2 antibodies often stems from:

• Inadequate validation: Using antibodies without proper specificity testing

• Lot-to-lot variation: Particularly with polyclonal antibodies

• Protocol inconsistencies: Minor changes in fixation, blocking, or washing steps

• Cell culture variables: Confluence levels significantly affect tight junction formation

• Sample handling differences: Protein degradation during extraction

• Antibody storage issues: Repeated freeze-thaw cycles or improper storage

• Insufficient controls: Lacking positive and negative controls

To improve reproducibility, maintain detailed protocols, use antibodies with validation data, include appropriate controls, and standardize experimental conditions across experiments .

How should ZO-2 antibody data be reported in publications?

For transparent and reproducible reporting of ZO-2 antibody data:

• Antibody identification:

  • Supplier name and location

  • Catalog number

  • Clone ID for monoclonals

  • Lot number (especially important for polyclonals)

  • RRID (Research Resource Identifier) when available

• Validation evidence:

  • Description of validation experiments performed

  • References to prior validation studies

  • Images of positive and negative controls

• Experimental details:

  • Complete protocol including blocking, dilutions, incubation times/temperatures

  • Imaging parameters (exposure times, gain settings)

  • Quantification methods

• Raw data availability:

  • Consider providing unprocessed images as supplementary material

  • Deposit original data in appropriate repositories

Following these reporting standards enhances research transparency and reproducibility .

How can I use ZO-2 antibodies in advanced imaging techniques?

ZO-2 antibodies can be employed in cutting-edge imaging applications:

• Super-resolution microscopy (STORM, PALM, SIM):

  • Requires bright, photostable fluorophore-conjugated secondary antibodies

  • Higher primary antibody dilutions often yield better results (1:500-1:1000)

  • Smaller probes (Fab fragments, nanobodies) may improve resolution

• Live-cell imaging:

  • Consider cell-permeable antibodies or antibody fragments

  • Fluorescent protein fusion constructs as alternatives

  • Minimize phototoxicity with appropriate imaging parameters

• Expansion microscopy:

  • Test antibody compatibility with expansion protocols

  • May require post-expansion staining for some antibodies

• Correlative light-electron microscopy:

  • Use gold-conjugated secondary antibodies

  • Verify antibody performance in EM fixation conditions

What are the advantages of using recombinant ZO-2 antibodies over traditional monoclonal antibodies?

Recombinant antibody technology offers several advantages for ZO-2 research:

• Consistency: Defined amino acid sequence eliminates lot-to-lot variation

• Reproducibility: Consistent performance across experiments

• Customizability: Can be engineered with specific tags or functional domains

• Renewable source: No hybridoma required, eliminating cell line stability concerns

• Reduced background: Often shows cleaner signals in many applications

• Ethical considerations: Reduces animal use in antibody production

• Sequence transparency: Known sequence enables better characterization

Several initiatives, including NeuroMab, have begun converting traditional monoclonal antibodies to recombinant formats and making sequences available through public repositories like Addgene .

How do I address non-specific binding when using ZO-2 antibodies?

Non-specific binding can be minimized through several approaches:

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time (1-2 hours at room temperature)

  • Add 0.1-0.3% Triton X-100 to blocking solution

• Antibody dilution:

  • Titrate to find optimal concentration

  • Higher dilutions often reduce background

• Washing stringency:

  • Increase wash duration and number of washes

  • Add 0.05-0.1% Tween-20 to wash buffers

• Pre-adsorption:

  • Pre-incubate antibody with extracts from ZO-2 knockout cells

  • Commercial pre-adsorption kits are available

• Secondary antibody controls:

  • Include secondary-only controls to identify non-specific binding

  • Consider trying secondaries from different suppliers

Why might ZO-2 antibodies show different staining patterns in different tissues?

Variability in ZO-2 staining patterns across tissues may reflect biological and technical factors:

• Biological variables:

  • Tissue-specific ZO-2 isoform expression

  • Different post-translational modifications

  • Varying interaction partners masking epitopes

  • Tissue-specific subcellular localization

• Technical considerations:

  • Tissue-dependent fixation effects

  • Differences in tissue permeability to antibodies

  • Autofluorescence variations

  • Antigen retrieval effectiveness

When comparing ZO-2 expression across tissues:

• Use consistent processing methods

• Include positive control tissues

• Consider dual staining with multiple ZO-2 antibodies

• Validate with complementary techniques (in situ hybridization, RNA-seq)

How can ZO-2 antibody studies be complemented with genetic approaches?

Integrating antibody-based detection with genetic methods provides more robust and comprehensive analysis:

• CRISPR/Cas9 ZO-2 knockout:

  • Creates definitive negative controls for antibody validation

  • Allows phenotypic assessment of ZO-2 loss

• ZO-2 knockdown:

  • siRNA or shRNA approaches for partial reduction

  • Useful for dose-response studies

• Epitope tagging:

  • Knock-in of FLAG, HA, or other tags

  • Enables detection with highly specific tag antibodies

• Fluorescent protein fusions:

  • GFP-ZO-2 for live imaging

  • Can validate antibody localization patterns

• Domain deletion/mutation:

  • Test domain-specific antibody reactivity

  • Map functional domains in parallel with antibody epitopes

What are the best practices for quantifying ZO-2 expression levels?

For accurate quantification of ZO-2 levels:

• Western blot quantification:

  • Use graduated loading controls

  • Verify linear detection range

  • Include recombinant protein standards

  • Normalize to multiple housekeeping proteins

  • Use digital image acquisition (avoid film)

• Immunofluorescence quantification:

  • Standardize image acquisition parameters

  • Capture multiple random fields

  • Use automated measurement tools

  • Include internal reference standards

  • Account for background fluorescence

• Flow cytometry:

  • Optimize permeabilization for intracellular staining

  • Use fluorescence minus one (FMO) controls

  • Report median fluorescence intensity (MFI)

• Statistical considerations:

  • Perform biological (not just technical) replicates

  • Report sample sizes and statistical tests

  • Consider power analysis for sample size determination